EBITDA: Income before interest, taxes, depreciation and amortization.
Knight Therapeutics Inc. (T.GUD) had EBITDA of 13.37M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
-2.75M |
|
-- |
|
-- |
|
-- |
|
0.47M |
|
-- |
|
-1.39M |
|
-1.39M |
|
-2.75M |
|
-2.75M |
|
-2.75M |
|
-2.75M |
|
0.47M |
|
|
EBITDA |
13.37M |
99.66M |
|
99.66M |
|
-0.03 |
|
-0.03 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
761.39M |
|
-- |
|
-- |
|
-- |
|
204.61M |
|
556.78M |
|
215.76M |
|
556.78M |
|
99.68M |
|
| Cash Flow Statement Financials | |
24.75M |
|
-51.25M |
|
29.19M |
|
58.17M |
|
59.45M |
|
1.29M |
|
3.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.62 |
|
-- |
|
-- |
|
0.10 |
|
0.14 |
|
45.92% |
|
0.53% |
|
0.53% |
|
-- |
|
-1.58% |
|
-3.12% |
|
23.75M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.46 |
|
0.93 |
|
96.36 |
|
-0.49% |
|
-1.28% |
|
-0.36% |
|
-0.45% |
|
7.69 |
|
0.24 |
|
0.25 |
|